Tailored chemo shows promise for stomach cancer in early trial
NCT ID NCT05733689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adjusting chemotherapy based on how a patient's tumor responds can improve outcomes for people with stomach or gastroesophageal junction cancer. About 20 participants with stage IB to III disease will receive standard chemo combinations (FLOT, FOLFOX, or FOLFIRI), and their treatment plan may be changed based on tumor response. The main goal is to see if this personalized approach helps more patients complete their planned treatment and proceed to curative surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy combinations (FLOT, FOLFOX, FOLFIRI)
What this could lead to
If successful, this could show that tailoring chemotherapy based on early response helps more patients complete treatment and have successful surgery.
What could go wrong
This is a very early phase 1 trial with only 20 people, so results may not apply widely. The chemotherapy combinations have known side effects like nerve damage, low blood counts, and digestive issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Chao Family Comprehensive Cancer Center, University
RECRUITINGOrange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••